 Best Practices in Adult ADHD: Neurobiology, Pharmacology, and Emerging Treatments PsychCast™ (85 Minutes)
Faculty: Lenard A. Adler, MD, Thomas J. Spencer, MD, Mark A. Stein, PhD, and Jeffrey H. Newcorn, MD
This CME Expert Review PsychCast™ is jointly sponsored by the Mount Sinai School of Medicine and MBL Communications.
Release Date: October 2008
Termination Date: October 31, 2010
Estimated time to complete this activity: 1.5 hours
Medium: The content is delivered by PsychCast™ with a PDF or web-based Posttest
Acknowledgment of Commercial Support: Funding for this activity has been provided by an educational grant from Shire Pharmaceuticals Inc.
CME Course Director: This activity has been peer-reviewed and approved by Eric Hollander, MD, Chair and Professor of Psychiatry at Mount Sinai School of Medicine. Review Date: August 27, 2008
Faculty Affiliation
Dr. Adler is associate professor of psychiatry and child and adolescent psychiatry, and director of the Adult ADHD Program, both at the New York University Langone School of Medicine.
Dr. Spencer is associate professor of psychiatry at Harvard Medical School and associate director of the Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital in Boston.
Dr. Stein is professor in the Department of Psychiatry a the University of Illinois in Chicago and director of the Adult ADHD Clinic.
Dr. Newcorn is associate professor in the Department of Psychiatry at the Mount Sinai School of Medicine in New York City.
Faculty Disclosure Policy Statement
It is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
Faculty Disclosure
Dr. Adler is a consultant to and on the advisory boards of Abbott, Cephalon, Cortex, Eli Lilly, Novartis, Ortho-McNeil, Janssen, Johnson and Johnson, Merck, New River, Organon, Pfizer, sanofi-aventis, and Shire; is on the speaker’s bureaus of Eli Lilly and Shire; and receives grant/research support from Abbott, Bristol-Myers Squibb, Cephalon, Cortex, Eli Lilly, Janssen, Johnson and Johnson, Merck, National Institute of Drug Abuse, New River, Novartis, Ortho-McNeil, Pfizer, and Shire. Dr. Adler mentions the following experimental/off-label medications for adult ADHD: bupropion and modafinil.
Dr. Newcorn is a consultant to Abbott, Biobehavioral Diagnostics, Eli Lilly, Lupin, Novartis, Ortho-McNeil, Psychogenics, sanofi-aventis, and Shire; and receives research support from Eli Lilly and Ortho-McNeil. Dr. Newcorn mentions the following experimental/off-label medications for adult ADHD: bupropion, clonidine, guanfacine, modafinil, tricyclic antidepressants, and velafaxine.
Dr. Spencer is a speaker for Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Ortho-McNeil, and Shire; is on the advisory boards of Cephalon, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Ortho-McNeil, Pfizer, and Shire; and receives research support from Cephalon, Eli Lilly, GlaxoSmithKline, Janssen, National Institute of Mental Health, Novartis, Ortho-McNeil, Pfizer, and Shire.
Dr. Stein is a consultant/advisor to Abbott, Novartis, and Pfizer; is a speaker for Novartis and Ortho-McNeil; and receives research support from Eli Lilly, National Institute of Mental Health, Organon, Ortho-McNeil, and Pfizer.
Dr. Hollander reports no affiliation with or financial interest in any organization that may pose a conflict of interest.
Learning Objectives
• Review the neurobiology of attention-deficit/hyperactivity disorder (ADHD), including genetic influences and neuroanatomical and neurochemical factors.
• Describe the current practices and controversies surrounding stimulant therapy in adults with ADHD.
• Discuss the benefits of nonstimulant treatment, psychosocial treatment, and emerging treatment options for adult ADHD.
Target Audience: This activity is designed to meet the educational needs of primary care physicians and psychiatrists.
Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclaimer: These are the opinions of the authors not of the sponsors or supporters. For more information, contact MBL Communications at cme@mblcommunications.com.
Minimum Hardware/Software Requirements
Macintosh: PowerPC processor, Mac OS 8.6, 9.0.4, 9.1, or Mac OS X, 64MB of RAM, 24MB of available hard-disk space, and Safari 1.x or 2.x.
Windows PC: Intel Pentium processor, Microsoft Windows 95 OSR 2.0, Windows 98 and 98 SE, Windows Millennium Edition, Windows NT 4.0 with Service Pack 5, Windows 2000, or Windows XP, 64MB of RAM, 24MB of available hard-disk space, and Internet Explorer 6.x and newer or Firefox 1.x and newer.
This CME Activity and Posttest information file is a PDF (Portable Document Format) document. To view this file, you will need Adobe Acrobat Reader, which is available free at www.adobe.com. Follow the instructions on that page to download and install the software.
Best Practices in Adult ADHD: Neurology, Pharmacology, and Emerging Treatment PsychCast™ (85 Minutes)
Faculty: Lenard A. Adler, MD, Thomas J. Spencer, MD, Mark A. Stein, PhD, and Jeffrey H. Newcorn, MD
Abstract
Treatment of attention-deficit/hyperactivity disorder (ADHD) may positively impact the neurobiology of adult patients with ADHD. Treatment may also minimize impairment from core symptoms and may alter the course of co-morbid disorders such as depression and substance use disorder. However, much of the information on stimulant use in adult ADHD comes from studies conducted in children, and it remains unclear whether there is a difference between children and adults when it comes to the side effects and tolerability of ADHD treatments. It is known that clinical presentation differs between adults and children, with adults demonstrating a higher percentage of mood disorders. Current treatments for adult ADHD include psychosocial therapies and pharmacologic therapies, the latter of which include the stimulants d-methylphenidate extended release (XR), OROS methylphenidate, lisdexamfetamine, and mixed amphetamine salts XR; and the nonstimulant atomoxetine, a selective norepinephrine reuptake inhibitor. There is need for additional study of treatment strategies for adult ADHD. Although all classes of ADHD medications are approved in adults, there are fewer approved formulations for adults than for children. Efficacy in adults is more subjective than in children, which may affect how efficacy rates for adult treatments are calculated. Adults also present a greater diversion risk than children. In addition, there are several new and emerging medication treatments worth considering.
This Expert Roundtable PsychCast™ represents part 2 of a 3-part supplement series on adult ADHD led by Lenard A. Adler, MD. In this activity, Thomas J. Spencer, MD, discusses the neurobiology and genetics of adult ADHD; Mark A. Stein, PhD, discusses stimulant therapy; and Jeffrey H. Newcorn, MD, reviews nonstimulants and psychosocial treatments.
To receive credit for this activity: Listen to the PsychCast™, reflect on the material presented, and complete the online CME Posttest/Evaluation here or to submit the CME Posttest/Evaluation by mail or fax, download a PDF here. To obtain credit, you should score 70% or better. The estimated time to complete the PsychCast™ and the posttest and evaluation is 1 hour. Successful completion of the posttest and evaluation will allow you to claim credit and print a certificate.
Early submission of this posttest is encouraged: please submit by October 1, 2010 to be eligible for credit. If you have any questions, please e-mail cme@mblcommunications.com.
Read the extended CME supplement related to this PsychCast™ activity here
Supported by Shire Pharmaceuticals Inc. |
Subscribe |
Download |
|
|
|
|
